NFE2L2 and non-small cell lung carcinoma: Preclinical and clinical studies in NSCLC have suggested that KEAP1 and NFE2L2 mutations confer resistance to chemotherapy, radiotherapy, and targeted agents (Ji et al., 2022; Scalera et al., 2022).